Introduction {#s1}
============

Renal cell carcinoma (RCC) is the seventh most frequently diagnosed malignancy in men and the ninth in women, representing \~2--3% of cancer diagnoses in adults ([@B1]). RCC includes a group of tumors with heterogenic features in terms of genetic landscape, growth pattern, and metastatic potential ([@B2]). Clear cell RCC (ccRCC) is the most frequently diagnosed histotype (75--80%), followed by papillary RCC (10--15%), chromophobe RCC (5%), collecting duct/medullary carcinomas (1--2%), and translocation-associated RCC (\<1%), plus \~5% of unclassified cases ([@B3]). The central role played by angiogenesis in RCC pathogenesis is mediated by signaling cascades involving multiple factors, such as pVHL (von Hippel-Lindau tumor suppressor protein), HIF-1α (hypoxia inducible factor 1 subunit alpha), VEGF (vascular endothelial growth factor), PDGF (platelet-derived growth factor), and mTOR (mammalian target of rapamycin) ([@B4]--[@B7]). At the present time, approved targeted therapy agents in advanced RCC include bevacizumab, a monoclonal antibody that blocks VEGF-A by preventing its binding to the VEGF receptor; tyrosine kinase inhibitors (TKIs) that mainly exert their activity by inhibiting the VEGF receptor and include sorafenib, sunitinib, pazopanib, and axitinib; inhibitors of the mTOR complex, such as temsirolimus and everolimus. The increased RCC risk in immunocompromised patients, the abundance of tumor-infiltrating lymphocytes, as well as the anecdotal reports of spontaneous tumor regressions provide evidence supporting the potential effectiveness of immunotherapy in RCC. Before the advent of the TKIs era, interferon-alpha (IFN-α) and high-dose interleukin-2 (HD IL-2) were among the few active systemic therapeutic options, although sustained responses were obtained only in a small fraction of patients with mRCC ([@B8]--[@B13]). An exciting breakthrough in the development of immunotherapy of RCC has been achieved with agents directed against molecules that act as critical regulators of tumor-induced immune suppression, such as nivolumab, directed against PD-1 (programmed death-1), and ipilimumab directed against CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4).

This review provides a comprehensive appraisal of prognostic and predictive factors tested in patients with ccRCC treated with anti-angiogenic agents, with a focus on those with a potential to affect therapeutic decisions---for example, the choice of an anti-angiogenic vs. an immunotherapy agent. Biomarkers predictive of toxicity of anti-angiogenic agents have also been presented and discussed.

Prognostic and Predictive Biomarkers {#s2}
====================================

Clinical and Biochemistry Markers
---------------------------------

Several prognostic models have been developed over the past years ([@B14]--[@B16]). The Memorial Sloan-Kettering Cancer Center (MSKCC) classification system ([@B17]--[@B19]) was developed during the cytokine era. Subsequently, with the advent of targeted therapies (TTs), Heng et al. ([@B20], [@B21]) validated the International Metastatic RCC Database Consortium (IMDC) risk score. The MSKCC or Motzer criteria classify patients according to three serum factors (lactate dehydrogenase-LDH, hemoglobin, and calcium) and two clinical factors (Karnofsky performance status and interval from diagnosis to treatment). These variables correlate significantly with overall survival (OS) ([Table 1](#T1){ref-type="table"}). The IMDC model incorporates six factors, which include two clinical factors (Karnofsky performance status and time from initial RCC diagnosis to the start of therapy), and four serum markers (hemoglobin, calcium, neutrophils, and platelets). In this model, pre-treatment factors independently associated with a shorter OS by multivariate analysis are hemoglobin \< lower limit of normal (LLN) (*p* \< 0.0001), corrected calcium \> ULN (upper limit of normal) (*p* = 0.0006), Karnofsky performance status \<80% (*p* \< 0.0001), time from diagnosis to treatment \<1 year (*p* = 0.01), neutrophils \> ULN (*p* \< 0.0001), and platelets \> ULN (*p* = 0.01). Based on these factors, different overall survivals were reported in the favorable-risk group (no prognostic factors, *n* = 133, median OS = 43.2 months); intermediate-risk group (1--2 prognostic factors, *n* = 301, median OS = 22.5 months); and poor-risk group (3--6 prognostic factors, *n* = 152, median OS = 7.8 months) ([Table 2](#T2){ref-type="table"}). The importance of such a prognostic classification lies in its implications for treatment choice, as temsirolimus is approved only in patients at poor prognosis and novel immunotherapy combination ipilimumab plus nivolumab is approved in patients at intermediate and poor prognosis ([@B22]--[@B31]).

###### 

MSKCC score system.

  **KARNOFSKY PS**                     **\<80%**                                                         
  ------------------------------------ -------------------------- -------------------------------------- -----------------------------
  Hemoglobin                           \<lower normal limit                                              
  Lactate dehydrogenase                1.5 × upper normal limit                                          
  Corrected serum calcium              \>10 mg/dL                                                        
  Period from diagnosis to treatment   \<1 year                                                          
  **Prognosis**                        **Score**                  **Median overall survival (months)**   **Survival at 3 years (%)**
  Good                                 0                          30                                     45
  Intermediate                         1--2                       14                                     17
  Poor                                 3--5                       5                                      2

*MSKCC, Memorial Sloan Kattering Cancer Center*.

###### 

IMDC risk group classification.

  **KARNOFSKY PS**                     **\<80%**                                                     
  ------------------------------------ ---------------------- -------------------------------------- -----------------------------
  Hemoglobin                           \<lower normal limit                                          
  Corrected serum calcium              \>10 mg/dL                                                    
  Period from diagnosis to treatment   \<1 year                                                      
  Neutrophil counts                    \>upper normal limit                                          
  Platelet count                       \>upper normal limit                                          
  **Prognosis**                        **Score**              **Median overall survival (months)**   **Survival at 2 years (%)**
  Good                                 0                      NR                                     75
  Intermediate                         1--2                   27 mos.                                53
  Poor                                 3--6                   8.8 mos.                               7

*IMDC, International Metastatic RCC Database Consortium*.

Histology Biomarkers
--------------------

Several histology factors predictive of RCC recurrence have been identified, including pathologic stage, nuclear Fuhrman grade, histology variant, sarcomatoid differentiation or necrosis, vascular invasion, and invasion of the collector system. The nuclear Fuhrman grade is the only histology marker that proved to be independently associated with OS in RCC ([@B15], [@B16]). Tumor stage and grade show prognostic value in most multivariate models ([@B32]).One retrospective pathology study showed that more than fifty per cent of the revised clear cell RCC samples had distinctive features from those associated with classical clear cell carcinoma, which suggests that clear cell RCC should be further divided in additional classes ([@B33]--[@B37]). Of note, RCC patients with a higher clear cell component are more likely to benefit most from VEGF-TT ([@B38]). Importantly, different histologies, such as clear cell, papillary, and chromophobe RCCs as well as benign oncocytomas have a different genetic background ([@B39]).

Carbonic anhydrase IX (CAIX) is a protein that converts carbon dioxide into carbonic acid, which is essential for pH homeostasis in hypoxic conditions. CAIX can be assessed at immunohistochemistry and is induced by hypoxia. Higher CAIX expression levels predict longer survival in localized RCC and mRCC and have been associated with response to sorafenib treatment ([@B40]). C-X-C chemokine receptor type 4 (CXCR4) is another promising biomarker, which may cross-talk with the VEGF pathways. D\'Alterio et al. ([@B41]) included 62 mccRCC patients treated with first-line sunitinib and evaluated CXCR4 expression at immunohistochemistry. An association between high CXCR4 expression and poor response to sunitinib was detected. Another study revealed that low or no CXCR4 expression in patients receiving sorafenib was associated with higher PFS (20.0 ± 5.9 months) than intermediate or high CXCR4 (6.0 ± 0.8 months) (*p* = 0.038) expression; however, no correlation was found between low or no CXCR4 expression and OS ([@B42]).

Higher levels of HIF-1α or HIF-2α at immunohistochemistry correlated with complete or a partial response to sunitinib therapy; particularly high levels of HIF-1α at baseline was associated with longer PFS (42.0 weeks, 95% CI 31.0--56.3) than low HIF-1α levels (30.4 weeks, 95% CI 22.2--43.9, HR = 1.55, *p* = 0.034) ([@B43]). Combined immunohistochemistry analysis showed no statistically significant associations between time-to-progression or OS and either HIF-1α or CAIX tumor expression. Nevertheless, PFS was significantly different between HIF-1α-low groups 0--2 (i.e., 0--50%) and HIF-1α-high groups 3--4 (i.e., 51--100%). The same results were obtained in another study in which sunitinib-treated patients reached a significantly longer PFS in the lower HIF-1α ([@B44]).

Serum Biomarkers
----------------

Angiogenesis is implicated in RCC tumorigenesis with a multiple involved factor, including VHL, HIF-1α, VEGF, PDGF, and PI3K/PKB/mTOR (Phosphoinositide 3-kinases/Protein Kinase B) signaling ([@B1], [@B4]--[@B7], [@B9]). Several VEGF pathway inhibitors have been approved for the treatment of metastatic RCC, including sunitinib, bevacizumab, pazopanib, axitinib, and cabozantinib ([@B22], [@B23], [@B26]--[@B30]). As a result of alternative splicing of the eight-exon VEGF-A gene, VEGF-A presents several isoforms, and its expression is associated with both histology and prognosis ([@B45]). Multiple VEGF receptors have also been identified. While VEGFR1, VEGFR2 are expressed on vascular endothelial cells, VEGFR3 is expressed on lymphatic endothelial cells ([@B46]). VEGFR2 is the primary transducer of extracellular VEGF, mediating endothelial cell proliferation, migration, and resistance to apoptosis ([@B47]). Alternative splicing of *KDR*, the gene that encodes VEGFR2, results in a soluble 679-amino acid truncated extracellular-domain product (sVEGFR2) ([@B48]). Multiple clinical studies have shown associations between markers of VEGF activation and outcomes in patients treated with sorafenib and sunitinib. In a retrospective analysis of 903 RCC patients randomized to sorafenib vs. placebo, baseline VEGF levels were associated with both PFS and OS in univariate analysis (PFS, *P* = 0.0013; OS, *P* = 0.0009) ([@B49]). In a population of 63 patients receiving sunitinib, variations of serum levels of both sVEGFR2 (soluble VEGFR2) and sVEGFR3 during treatment correlated significantly with the objective response rate (ORR) ([@B50]). In another study conducted in patients receiving sunitinib after prior bevacizumab, low baseline levels of sVEGFR3 was also predictive of longer PFS ([@B51]).

Apart from VEGF-A, other soluble factors of predictive and prognostic value include multiple cytokines \[e.g., IL-6, that can be directly secreted by cancer cells ([@B52])\] that have been variously implicated in the neoplastic process. In a study population involving 344 RCC patients randomized to either pazopanib or placebo in a phase III trial, serum concentrations at baseline of IL-8, hepatocyte growth factor (HGF), IL-6 and tissue inhibitor of metalloproteinases (TIMP)-1 were associated with a worse prognosis independently on the treatment arm, with some findings suggesting that baseline cytokine levels may be associated with a distinct sensitivity to pazopanib ([@B53]). In fact, patients with low vs. high baseline IL-6 levels showed a HR for survival favoring pazopanib compared to placebo of 0.55 vs. 0.31 ([@B52]). Importantly, IL-6, TIMP-1 and osteopontin were successfully incorporated in a prognostic model including five clinical variables and showing improved accuracy with respect to the Heng model, with a concordance-index of 0.75 vs. 0.67, respectively ([@B54]).

Genetic Biomarkers
------------------

Several genetic factors have been investigated in RCC, but none of them have been assessed in randomized clinical trials ([@B55], [@B56]). Specific gene expression and single nucleotide polymorphisms (SNPs) can predict activity of TTs. Some studies suggest that SNPs in vascular endothelial growth factor receptor 3 (VEGFR3), cytochrome P450 3A5 (CYP3A5\*1), IL-8, fibroblast growth factor receptor 2 (FGFR2), nuclear receptor subfamily 1 group I member 2 (NR1I2), and ATP binding cassette subfamily B member 1 (ABCB1) may predict efficacy and tolerance. No molecular/genetic biomarker has been validated in prospective clinical trials and can be used in clinical practice.

Some of the most studied genetic markers in RCC are: VHLSW1/SNF chromatin remodeling complex gene polybromo 1 (PBRM1)BRCA1 associated protein-1 (BAP1)

More than 90% of sporadic ccRCCs present loss of function of VHL, a tumor suppressor gene located on chromosome 3p. In normal tissue, VHL causes proteolysis of HIF-1α, but in RCC, VHL inactivation is associated with higher levels of HIF-1α, increased transcription of genes implicated in angiogenesis and tumorigenesis, such as VEGF and PDGF as well as activation of the PI3-K/PKB/mTOR pathway, that is involved in cancer progression ([@B57]). VHL loss is often the result of gene mutation or promoter hyper-methylation in RCC, but its implications in response to treatment are unknown. Choueiri et al. attempted to assess the relationship between VHL gene status and clinical outcomes to evaluate mRCC patients receiving VEGFR inhibitors. The response rate (RR) was 41% in mRCC patients with VHL inactivation vs. 31% in the wild-type VHL subgroup (*p* = 0.34). The presence of aberrant VHL gene, particularly loss-of-function mutations (frameshift, nonsense, splice, and in-frame deletions/insertions) corresponded to a 52% of RR. Thus, VHL loss-of-function mutations represent an independent prognostic factor linked to improved RR, but do not reflect progression-free survival (PFS) or OS. Similar findings were obtained for patients treated with both pazopanib and sorafenib ([@B58]--[@B61]). The PBRM1 /BAF180 tumor suppressor gene is mutated in 30--50% of ccRCC cases ([@B62]--[@B64]). PBRM1 is implicated in cell proliferation ([@B65]), and is found mutated at early stages of ccRCC ([@B35]). Mutations of PBRM1 are reported in small (\<4 cm) RCC masses with an aggressive clinical behavior. Mutations of BAP1, a ubiquitin carboxyl-terminal hydrolase, correlate with negative histologic features (e.g., high nuclear grade) and poor cancer-specific survival. Inactivating mutations are reported in 15% of ccRCC. Mutation in the BAF180 gene excludes mutation of the BAP1 gene in most cases. Patients with BAP1-mutant vs. those with PBRM1-mutant RCC have shorter survival (4.6 years, 95% CI 2.1--7.2 vs. 10.6 years, 95% CI 9.8--11.5; HR = 2.7; 95% CI 0.99--7.6, *p* = 0.044) ([@B26], [@B66]). Furthermore, patients with BAP1-mutated tumors vs. PBRM1-mutated tumors are at higher risk of presenting metastatic dissemination (*p* \< 0.023) and locally advanced disease (*p* \< 0.042). In patients with localized RCC at diagnosis, a shorter relapse-free survival (RFS) was reported in BAP1 mutated disease (*p* = 0.059), with an uncertain association with survival ([@B67], [@B68]). BAP1 and PBRM1 appear as promising genetic prognostic markers for RCC and require prospective validation.

Single-Nucleotide Polymorphisms
-------------------------------

As recently shown, there are some single nucleotide polymorphisms (SNPs) (e.g., in genes involved in the VEGF pathway) that are associated with the risk of RCC ([@B69], [@B70]) as well as with RR and adverse events in patients receiving TTs. An analysis of 397 RCC patients receiving pazopanib assessed the clinical significance of 27 polymorphisms in 13 genes involved in angiogenesis, metabolism and drug transport. Three SNPs in IL-8 and HIF-1α and five SNPs in HIF-1α, NR1I2, and VEGFA were significantly associated with PFS and RR (*p* ≤ 0.05). RR was lower in patients with the VEGFA 1498CC vs. 1498TT genotype (33 vs. 51%, *p* ≤ 0.05) ([@B71]). Median PFS was significantly shorter in patients with two IL-8 polymorphisms associated with higher IL-8 gene expression than in those with wild-type IL-8 (27 vs. 48 weeks) ([@B72]). Furthermore, IL-8 has can potentially mediate resistance to TKIs ([@B73]). Variant alleles of IL-8 polymorphisms have been associated with worse OS in pazopanib- or sunitinib-treated mRCC patients ([@B74]). Another prospective study assessed response and toxicity to sunitinib in patients with ccRCC. Of the sixteen polymorphisms assessed in nine genes, Two VEGFR3 missense polymorphisms predicted a shorter PFS and a variant of CYP3A5\*1 predicted higher toxicity at multivariate analysis. While VEGF or VEGFR SNPs were associated with outcomes, patients presenting VEGF SNP 936 and VEGFR2 SNP 889 had longer OS after adjusting for their risk group (*p* = 0.03) ([@B75], [@B76]). A retrospective study including 136 patients with metastatic ccRCC receiving sunitinib showed that SNPs in CYP3A5, ligand-activated nuclear receptor NR1I3, and ABCB1VEGF and VEGFR-2 were able to predict survival ([@B77]). Since most SNPs found to be associated with outcome have a low frequency, their impact in clinical practice is to be further ascertained, especially in-patient populations including different ethnicities. In an analysis of 138 VEGF SNPs assessed in patients treated with bevacizumab enrolled in the AVOREN trial ([@B78]) VEGFR1 SNP codifying for aminoacids located in its tyrosine-kinase domain associated with poor PFS (HR = 1.81, 95% CI 1.08--3.05, *p* = 0.033), although no association was found with OS (HR = 0.91, 95% CI 0.45--1.82, *p* = 0.78). In patients receiving axitinib in the AXIS (Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma) trial those with VEGFA rs699947 and rs833061 polymorphisms showed longer OS (27.0 vs. 13.4 months, HR = 0.39, *p* = 0.015), while those positive for the VEGFR2 rs2071559 polymorphism treated with sorafenib in this trial, had longer OS (26.8 vs. 13.8 months, HR = 0.41, *p* = 0.030). At multivariate analysis only VEGFR2 rs2071559 predicted PFS (*p* = 0.0053) and OS (*p* = 0.0027) in patients receiving sorafenib ([@B45]). Another study including 121 mRCC patients receiving sunitinib found the VEGFR1 SNP rs9582036 to be associated with OS ([@B47]). VEGFA SNPs have been associated with axitinib efficacy ([@B78], [@B79]), while SNPs in VEGFR3 have been associated with sunitinib efficacy ([@B74]). A recent meta-analysis by Liu et al. ([@B80]) suggested that, although some VEGFR1 genetic variants, such as VEGFR1 rs9582036 and rs9554320, were involved in sunitinib therapy outcomes, their clinical use as predictive biomarkers was limited, considering the negative results of all existing studies.

MicroRNAs (miRNAs)
------------------

MicroRNAs are single-stranded RNAs that are not transduced into proteins, but affect gene expression at a post-transcriptional level and play a role in multiple pathologic processes, including cell growth (such as VHL), angiogenesis, apoptosis in RCC ([@B81]). High expression levels of a miRNA named miR-210 were associated with favorable pathologic features ccRCC patients in one study ([@B82]), while in others they correlated with increased risk of disease recurrence and shorter OS ([@B83], [@B84]). Lower miR-215 and miR-126 expression levels were associated with poor outcomes, whereas higher miR-126 expression levels were associated with a significantly longer disease-free survival and OS ([@B85]). One study found that simultaneous assessment of miR-21-5p, 142-3p, let-7g-5p, let- 7i-5p, and 424-5p and miR-204-5p could predict stage, grade, and time to progression ccRCC ([@B86]). Upregulation of miR942, miR-133a, miR-628-5p, and miR-484 was associated with sunitinib resistance in mRCC patients ([@B87]). Similarly, miR-141 downregulation was associated with epithelial-to-mesenchymal transition in ccRCC and poorer sunitinib response ([@B88]).

Molecular Sub-classifications
-----------------------------

ccRCC is an extremely complex and heterogeneous neoplasia involves different aberrant genes included VHL, TP53, chromatin modifier genes (PBRM1, SETD2, BAP1, ARID1A, MLL3, KDM5C, SMARCB1), PI3K/AKT/mTOR pathway genes (MTOR, PTEN, PIK3CA), MET, Hippo pathway gene NF2, NRF2-ARE pathway gene NFE2L2, and cell cycle genes (CDKN2A) ([@B89]). The understanding of the biomolecular processes involved in the proliferation and progression of ccRCC, allowed the identification of molecular subgroups with a prognostic and predictive value. First studies were conducted in non-metastatic ccRCC after nephrectomy in order to create a suitable prognostic model to predict the risk of recurrence. Brannon et al. identified two subtypes of RCC based on gene expression microarray data of 48 RCC: (1) ccA and (2) ccB with different biological signatures and prognoses. ccA tumors had a better prognosis than ccB, due to the overexpression of genes associated with hypoxia, angiogenesis, fatty acid metabolism, and organic acid metabolism, whereas ccB tumors overexpressed different aberrant genes that regulate EMT (epithelial--mesenchymal transition), identifying a more aggressive and immature subgroup ([@B90]). A subsequent meta-analysis of 480 ccRCC confirmed this classification, introducing a third cluster correlated with a wild type (WT) VHL expression profile and a non--clear cell phenotype ([@B91]). To standardize this model, Brooks et al. developed a novel molecular tool including 34-gene expression signature (ClearCode34) in 380 non-metastatic ccRCC patients from the TCGA dataset. At univariate analysis in the ccB subgroup a more recurrence rate occurred than ccA subgroup (HR: 2.3; 95% CI, 1.6--3.3; *p* = 4.3 × 10--6), with a higher risk of death from disease (HR, 2.9; 95% CI, 1.6--5.6; *p* = 0.0005) and from any cause vs. ccA subgroup (HR: 2.4; 95% CI, 1.6--3.7; *p* = 2.3 × 10--5) ([@B92]). The KIRC analysis working group evaluated mRNA/miRNA expression signatures on 446 ccRCC patients. An unsupervised clustering method identified four subsets (m1--m4), correlating with the prior reported ccA and ccB classification, particularly cluster m1 overlapped with the ccA group and, while ccB group corresponded to m2 and m3 sub-groups. Cluster m4 probably corresponded to the 15%, not included in the previous ccA/ccB classification ([@B93]). Subsequently, Chen et al. refined this classification, identifying three different subtypes of predominantly ccRCC carcinoma, CC-e.1, CC-e.2, CC-e.3, correlating with intermediate, better and worse OS, respectively. The previously reported ccA and ccB classification correlated with CC-e.2 (better prognosis) and CC-e.3 (worse prognosis), respectively; instead, considering the KIRC subtypes, m1 and m3 corresponded to CC-e.2 and CC-e.3, respectively, while CC-e.1 correlated with m2 and m4 ([@B89]).

Combining the results of these studies, we identify three main significant prognostic groups: Good prognosis: ccA, CC-e.2, and m1 groups, involved gene sets associated with chromatin remodeling processes and a higher frequency of PBRM1 mutations;Poor prognosis: ccB, CC-e.3, m3 groups, characterized by higher expression of cell cycle genes (CDKN2A) and hypoxia-related genes, EMT, hypermethylation, chromatin modifier genes mutation (SETD2 or BAP1), PI3K/AKT/mTOR pathway genes mutations (PTEN), and a metabolic shift (high glutathione and high dipeptide levels) ([@B94]);Intermediate prognosis: cluster 3, CC-e.1, m2, and m4, characterized by higher frequencies of BAP1 mutations and base-excision repair.

This prognostic molecular sub-classification was validated in non-metastatic patients, so how can these molecular sub-classifications predict the response to VEGFRi in mccRCC? de Velasco et al. evaluated the predictive value of ClearCode34 in the setting of systemic mccRCC treatment, showing a longer mOS for low-risk-ccA than high-risk-ccB subtypes \[27.6 vs.22.3 months (HR: 2.33; *p* = 0.039), respectively\]. On multivariable analyses and adjusting for IMDC groups, ccB remained associated with a worse OS (*p* = 0.044) ([@B95]). Recently, Beuselinck et al. identified four molecular ccRCC subgroups correlating with VEGFRi (sunitinib) treatment: (1) ccrcc1 ("c-myc-up") and ccrcc4 ("c-myc-up and immune-up") with shorter PFS, OS and poorer response to sunitinib, (2) ccrcc2 ("classical") and ccrcc3 ("normal-like") with longer OS and better sunitinib response (*p* \< 0.0001). Moreover, these four ccrcc groups correlated with the three subtypes ccA, ccB, and cluster-3 described by Brannon et al., particularly the poor-prognosis ccB group included ccrcc1 and ccrcc4 subgroups. The ccrcc1/ccrcc4 subtypes, resulted non-responders to sunitinib, and expressed common molecular characteristics like upregulation of MYC targets or a hypermethylated status associated with a less differentiated (76% of Fuhrman grade 4) phenotype. PBRM1 and aberrant VHL gene were most frequently identified in ccrcc1/ccrcc2. The ccrcc4 had higher inflammation score, sarcomatoid dedifferentiation, mutated BAP1, low frequency of aberrant VHL and wilde type PBRM1 ([@B96]). Patients labeled with ccrcc2-group had longer mPFS (20 months) and mOS (35 months) comparable to mPFS (24 months) and mOS (40 months) of ccrcc3-group, while the ccrcc1-group reached intermediate outcome (mPFS 12 months and mOS 22 months)and, the ccrcc4-group the poorest outcome (mPFS 8 months and mOS 14 months). To explain these different outcomes, an mRNA-expression of genes associated with angiogenesis was analyzed. The ccrcc2-3-group displayed the highest expression of the pro-angiogenic HIF-VEGF-VEGFR-pathway (HIF2A, VEGFA, VEGFR1, VEGFR2, and VEGFR3), particularly in tumors with a bi-allelic PBRM1 inactivation. In the poor responding ccrcc4-group, the neo-angiogenesis was poorly expressed ([@B97]). These data were confirmed by Verbiest et al., who showed a mPFS of 9 months for the ccrcc2 and ccrcc3, 5 months for ccrcc1, and 3 months for the ccrcc4-group, respectively (*P* = 0.011), with a mOS of 69, 19, and 5 months, respectively (*P* = 0.003). The ccrcc1-4 classification becomes a predictor of outcomes with VEGFRi (sunitinib and pazopanib) in the metastatic setting ([@B98], [@B99]). Angiogenesis expression signatures correlate with outcomes on VEGFRi treatments: high Angioscore correlates with good outcomes, generally associated with loss of PBRM1, conversely BAP1 loss associates with decreased angiogenic signaling and poor outcomes ([@B100]). Is there an overlap between these molecular sub-classifications and the IMDC risk groups, commonly used in clinical practice? Verbiest et al. correlated this molecular classification integrated with IMDC risk groups and sarcomatoid dedifferentiation, with the outcomes on first-line VEGFRi (sunitinib or pazopanib). The ccrcc2 group correlated with higher angiogenic gene expression, resulting more represented in IMDC good risk and poorly in IMDC poor risk (*p* \< 0.001). The ccrcc2 group and angiogenic gene expression correlated positively with longer PFS in IMDC intermediate-risk patients too (*p* = 0.006; *p* = 0.04). The ccrcc4- subtype was typically grouped in IMDC poor risk group, with low angiogenic gene expression, often with sarcomatoid differentiation and poorest outcomes ([@B101]). Therefore, the Angio phenotype correlates with superior outcomes, regardless IMDC risk category, although enrichment in angiogenesis gene expression is more represented in the good IMDC and part of intermediate IMDC risk group. In the era of immunotherapy with the approval of immuno-checkpoint inhibitors, the molecular classification gets a decisive role both as a carrier for understanding the connection mechanisms between the various aberrant molecular pathways involved with the immune system and as a predictor of outcomes. The expression of the immune checkpoint molecule programmed death-ligand 1 (PD-L1) on tumor cells and/or tumor-infiltrating immune cells (IC) has been reported to inhibit antitumor immunity and correlated with poor prognosis in mccRCC. VEGF plays a central role in cancer immune evasion, therefore anti-VEGF might reinforce the antitumor activity of antiPD-L1 through the T-cell enhancement, upregulating the major histocompatibility complex class I expression, and reducing myeloid immunosuppression. The expression of regulatory cytokines (IL10, TGFB1) and T-cell immunosuppressive molecules \[PD-L1-2, PD-1, LAG 3\], the presence of myeloid-derived suppressor cells as well as regulatory T cells correlate with VEGFRi treatment failure ([@B102]--[@B106]). The Immune signature, like the Angioscore correlated with molecular subtype (*p* = 0.0007). Recently the Checkmate 214 showed the efficacy of Ipilimumab plus Nivolumab in mccRCC, across all risk groups, although VEGFRi (sunitinib) performed better in good IMDC risk groups, due to the higher angiogenesis expression signatures, typical of this group ([@B107]). The previous sub-classifications identified the ccrcc4 (Beuselinck et al.), like Cluster 4 established by Hakimi et al. in the COMPARZ trial ([@B108]), as an inflamed subtype with moderate angiogenesis, but high immune infiltration, PD-L1 expression on tumor cells by IHC, and poor response to VEGFRi. IMDC poor risk groups were enriched either in immune-exhausted ccrcc4 tumors or in immune-cold ccrcc1 tumors ([@B101]). Considering the strongly correlation between the angiogenesis and the immune-system activation, several phase III trials have explored the new treatment paradigm: the association between VEGF/VEGFRi and immuno-checkpoint inhibitors ([@B107], [@B109]--[@B111]), with superb results in all IMDC risk-groups, molecular sub-groups, particularly in VEGFRi refractory patients, IMDC poor risk groups. A biological subgroups analysis of the phase 2 IMmotion150 study correlated the expression levels of angiogenesis (Angio), immune (Teff) and myeloid inflammation-associated genes (Myeloid) with outcomes. VEGFRi (Sunitinib) efficacy was higher in angiogenic tumors (AngioHigh), while the combination of atezolizumab + bevacizumab showed a larger clinical benefit in TeffHigh and in TeffHighMyeloidLow, particularly in TeffHighMyeloidHigh in which atezolizumab monotherapy failed, supporting the role of VEGFRi to overcome innate inflammation-mediated resistance ([@B112]). This data was confirmed by the phase III IMmotion151 trial. High Teff gene expression signatures (GE) or low angiogenesis GE were associated with longer PFS for atezolizumab plus bevacizumab vs. sunitinib, HR 0.76; 95% CI, 0.59--0.99; conversely, the efficacy was the same in high angiogenesis GE (HR, 0.95; 95% CI, 0.75--1.19). An interesting point was the further confirmation that angiogenesis GE was higher in favorable vs. intermediate to poor MSKCC risk groups (*p* = 4.28e−06). The main limit of these molecular classifications and its use in clinical practice, was the significant intratumor and inter-tumor (metastases) heterogeneity ([@B110]). Several analyses suggest that different interactions occur between the primary tumor and metastatic sites, and the coexistence of various sub-clones with different prognosis, particularly in intermediate IMDC risk group. Therefore, identification of a single driver gene based on single regional sequencing significantly under-estimates the true molecular tumor-assessment. The evidence suggest that multiple biopsy samples included metastases site, occur for a complete molecular analysis and to identify the clone with poor prognostic features ([@B113]--[@B115]).

Biomarkers Predictive of Adverse Events (AEs) of Anti-Angiogenic Therapy {#s3}
========================================================================

Most adverse events associated with anti-angiogenic therapy are the result of known either on-target or off-target inhibitory effects on tyrosine kinases inhibitors ([@B116]). For this reason, AEs may be associated with outcomes in some cases ([@B117]).

Hypertension
------------

Hypertension is a commonly reported adverse event in mccRCC patients treated with anti-angiogenic therapy, and correlates with a systemic dysfunction of microcirculation, activation of the endothelin-1 system, suppression of the renin-angiotensin system, inhibition of endothelial nitric oxide synthase, and increased vascular stiffness ([@B52], [@B53], [@B116]). Hypertension was initially reported to be associated with bevacizumab ([@B117]). Notably, in a phase III trial of bevacizumab plus IFN-α vs. IFN-α alone in patients with mRCC, patients in the bevacizumab arm who developed grade 2 hypertension showed a significantly longer PFS (13.2 months, 95% CI 10.6--15.5 vs. 8.0 months, 95% CI 5.9--8.6, *p* = 0.001) and OS (41.6 months, 95% CI 26.3--55.1 vs. 16.2 months, 95% CI 14.2--18.7, *p* = 0.001) than those who did not ([@B23]). In the multiple studies that explored the relationship between anti-angiogenic therapy and hypertension, a varying incidence of all-grade and grade 3/4 hypertension was reported, possibly as a result of differences in trial populations and timing and protocols for measuring blood pressure ([@B28]--[@B31]). A retrospective review involving 3 clinical trials showed that hypertension was associated with longer PFS, OS, and ORR in patients treated with sunitinib ([@B49], [@B50], [@B118], [@B119]). Patients enrolled in the AXIS trial who reported a diastolic blood pressure ≥90 mmHg within the first 8 or 12 weeks of randomization had a longer survival independently on the treatment arm: 20.7 months (95% CI 18.4--24.6) vs. 12.9 months (95% CI 10.1--20.4) in the axitinib group (*p* = 0.01), and 20.2 months (95% CI 17.1--32.0) vs. 14.8 months (95% CI 12.0--17.7) in the sorafenib group (*p* = 0.002) ([@B77]). These findings could not be confirmed by the Italian SAX study on real-world use of axitinib ([@B120]). A recent retrospective study showed that grade 3 hypertension affected positively OS in patients treated with pazopanib in real-world settings (HR = 0.22, 95% CI 0.05--0.8, *p* = 0.03) ([@B121]).

Hypothyroidism
--------------

Hypothyroidism is another frequent but generally mild adverse event known to be caused by anti-VEGFR TKIs ([@B122], [@B123]). The underlying biology of this adverse event includes multiple events/factors such as destructive thyroiditis, endothelial dysfunction, impaired iodine uptake, and reduced synthesis of thyroid hormone ([@B122]--[@B127]). Hypothyroidism has also been associated with outcome in patients receiving anti-angiogenic therapy. In one retrospective study by Wolter et al. ([@B128]) conducted in 40 mRCC patients, a longer mPFS (10.3 vs. 3.6 months) and mOS (18.2 vs. 6.6 months) were reported in patients with thyroid dysfunction than in those with normal thyroid function. Subclinical hypothyroidism diagnosed during the first 2 months of treatment has also been reported to be associated with survival ([@B128]--[@B130]). Inconsistent results were reported in a prospective study of 111 mRCC patients treated with sunitinib, that did not find any relationship between abnormal thyroid function and PFS (18.9 vs. 15.9 months) ([@B131]). Furthermore, one meta-analysis including 11 retrospective and prospective studies enrolling mRCC patients receiving sunitinib or sorafenib failed to identify any predictive value of hypothyroidism (HR for progression = 0.82, 95% CI 0.59--1.13, *p* = 0.22; 6 studies, 250 patients) ([@B132]). Thyroid dysfunction (both hypo and hyperthyroidism) may be associated with a longer PFS (HR = 0.12, 95% CI 0.02--0.78, *p* = 0.02) in patients treated with pazopanib ([@B121]).

Hand-Foot Syndrome
------------------

Hand-foot syndrome of any grade is approximately reported in up to half of patients receiving TKIs, with 9% patients showing grade 3 or 4 hand and foot syndrome. This adverse event is related to dermal endothelial cell apoptosis due to inhibition of VEGFR and PDGFR (platelet-derived growth factor receptor) in ([@B133]--[@B135]) TKIs may also mediate skin toxicity when secreted in the eccrine glands of the skin, which are rich in c-KIT ([@B128]--[@B130]). Pone retrospective study reported hand-foot syndrome to be associated with improved OS, PFS, and ORR. Hand-foot syndrome is able to predict PFS and OS ([@B136]).

Fatigue
-------

Fatigue is a commonly reported adverse event in patients treated with TKIs. Fatigue may be caused by the systemic inflammatory state related to the underlying malignancy, concomitant use of medications, anemia, or hypothyroidism and hypopituitarism ([@B137]). It was reported in up to half of treated patients ([@B138]). Patients with fatigue or asthenia seem to have improved clinical outcomes in terms of PFS and OS, although this may be the result of a longer on trial time ([@B139], [@B140]).

Optimization of Treatment Sequence {#s4}
==================================

At present time, there are no definitive data supporting one specific treatment sequence over the others, with multiple drugs recommended in the first, second and third-line setting ([Table 3](#T3){ref-type="table"}). In the new era of Immunotherapy, are VEGF-TKIs still a valid option for mccRCC treatment? The angiogenesis plays a central role in the ccRCC tumorigenesis and progression, regulating the immune landscape through abnormal tumor vessel formation, dysregulation of various immune cells and promoting an immunosuppressive tumor microenvironment. Therefore, anti-angiogenic therapy (sunitinib, pazopanib) remains a valid option in selected patients (VEGF-dependent favorable IMDC risk group first-line mccRCC) and enhances the activity of immunotherapy, modulating immune response. Different phase 3 trials evaluated or are evaluating combination of immune checkpoint inhibitors, such as anti PD-1 nivolumab and anti CTLA-4 ipilimumab, or anti PD-1/PDL-1 and VEGF/VEGFRi in first-line treatment, with superb results that will consequently change the therapeutic sequence in the first and second-line. The combination of VEGF/VEGFRi plus immune checkpoint inhibitors (IOVE) or Ipilimumab-Nivolumab (IO) will represent the gold standard treatment in first-line setting, across all IMDC risk group, particularly in poor risk patients with low angiogenic gene expression and sarcomatoid dedifferentiation. No data exist on the best first-line therapy. Recently Dudani et al., using the IMDC dataset, showed no significant differences in first-line outcomes for patients receiving IOVE combination vs. IO combination. ([@B141]). Hahn et al. conducted a Systematic Review and Network Meta-analysis of First-line Treatment of mccRCC. In the ITT population, cabozantinib \[surface under the cumulative ranking curves \[SUCRA\] 84%\], avelumab plus axitinib (SUCRA 68%), and pembrolizumab plus axitinib (SUCRA 82%) were superior to the other agents for PFS; pembrolizumab plus axitinib appeared superior for OS (SUCRA 95%); and atezolizumab demonstrated the lowest likelihood of AEs (SUCRA 100%). Findings were similar in the intermediate/poor-risk subgroup. Avelumab plus axitinib may be preferred in patients with favorable-risk disease. It is less clear what the superior treatment is for ORR, but avelumab plus axitinib, cabozantinib, and pembrolizumab plus axitinib performed better than other comparators ([@B142]). Until the recent past, clinicians selected second- and third-line therapies based on response to first-line therapy. Nevertheless, a retrospective review conducted by the IMDC demonstrated no correlation between both first- and second-line PFS (Pearson correlation coefficient 0.025, *p* = 0.59)and first- and second-line ORR (chi-squared trend test *p* = 0.17) ([@B143]). Elaidi et al. ([@B144]) showed that patients who remained on first-line TKI during 11--22 months benefited from a TKI re-challenge, rather than from second-line mTOR inhibitors (HR ≈ 0.5), with a median PFS of 9.4 months (5.9--12.2) vs. 3.9 months (3.0--5.5) (*p* = 0.003), whereas time-to-treatment failure was 8.0 months (5.5--11.0) vs. 3.6 months (3.0--4.6) (*p* = 0.009). PFS improved more with second-line VEGFR TKI if first-line VEFGR TKI was given for \>8 months (11.3 vs. 5.1 months, *p* = 0.009), suggesting continued VEGF inhibition may be a pertinent strategy in this subset of patients. The duration of first-line PFS is an independent prognostic variable but it is not predictive for PFS associated with subsequent therapy ([@B145]). Other authors found that the response and the PFS to a first-line TKI correlated with longer PFS and OS using everolimus as second-line treatment ([@B146]). The tumor shrinkage remains a prognostic factor, regardless of first-line therapy, and maximal tumor shrinkage (60--100%) was an independent predictor of longer OS ([@B147]). These data were confirmed by Basappa et al. ([@B148]), who identified a total tumor burden \<13 cm (*p* = 0.09) as an independent positive predictor of PFS, and a baseline number of metastases \<10 (*p* \< 0.001) and tumor burden above the diaphragm \<6.5 cm (*p* = 0.05) as independent predictors of OS. Tumor shrinkage associated significantly with longer OS (*p* \< 0.001) in patients receiving sunitinib. The lack of response to a VEGF/VEGFRi not preclude positive clinical outcomes on second-line VEGF/VEGFRi. A *post-hoc* analysis of the AXIS trial did not show significant differences in PFS or OS in responders vs. non-responders, as well as according to the duration of first-line sunitinib treatment; conversely the mOS was longer in patients with smaller vs. larger tumor burden, except in those treated with the cytokine-axitinib sequence ([@B149]). Furthermore, in the AXIS trial, the following factors were found to be associated with shorter OS: prior treatment with sunitinib, ECOG performance status ≥ 1, \<1 year from initial diagnosis to the first treatment, more than one metastatic site, particularly liver or bone metastases, anemia, neutrophilia, hypercalcemia or high level of LDH and alkaline phosphatase. These findings were confirmed by the RECORD-1 trial ([@B150]). Two additional studies concluded that everolimus treatment prolonged PFS, if the patient had received only one rather than two prior TKIs ([@B151]). Overall, the chosen systemic regimens, PFS, intensity and duration of response do not influence selection of the optimal sequence. The greater benefit to mRCC patients comes from an adequate sequential administration of available systemic regimens. Poor risk patients or non-responders show worse OS, PFS, and ORR due to the biology/aggressiveness of the tumor rather than sensitivity of the disease to a specific agent. Analysis of phase II and III trials of nivolumab in pretreated mRCC patients, showed longer OS regardless of first-line treatment (sunitinib, pazopanib, and IL-2), duration of first-line therapy (\<6 or ≥6 months). Conversely, the number of prior systemic regimens affected the OS: a longer mOS (not reached, 95% CI 19.8--not reached) was associated with only one previous treatment vs. two or more prior regimens (18.7 months, 95% CI 13.4--26, p not shown) ([@B104], [@B152]). Recently the results of two other trials evaluating, cabozantinib, and lenvatinib plus everolimus, showed superior RR and longer OS in second-line setting ([@B27], [@B104], [@B153], [@B154]). Treatment selection in this setting, is based on different factors, such as patient PS, contraindications and comorbidities, RCC subtype, safety profiles, and previous treatments. Bracarda et al. published a prognostic factor analyses from the AXIS trial, identifying axitinib as effective (post sunitinib) 2nd line therapy option for mccRCC with VEGF-dependent mRCC (AngioHigh), good/intermediate risk group, low tumor burden, without bone or liver metastases ([@B155]). In the new era of first line Immunotherapy, are VEGF-TKIs still a valid option for second-line mRCC treatment? To date no data, exist about post Immunotherapy (IO-IOVE) first-line therapy. Recently Auvray et al. reported the clinical outcomes of second line TKI, as part of Checkmate 214, showing 12 PR (36%), 13 SD (39%) and 5 PD (15%), evaluating 30 patients received subsequent TKI. The mPFS was 8 months ([@B5]--[@B13]), particularly 8 months ([@B5]--[@B16]) with sunitinib or pazopanib and 7 months (5--NA) with axitinib or cabozantinib. Overall PFS resulted longer in patients with long first-line response duration (≥6 months) vs. short response duration (\<6 months): 8 vs. 5 months (*p* = 0.03), respectively. Interesting, OS rate was 54% at 12 months. Toxicity was as expected: 42% developed at least one toxicity grade ≥3 ([@B156]). A retrospective study of mccRCC patients treated with second-line (2L) VEGFRi after first-line ICI. 2L TKI therapies included pazopanib, sunitinib, axitinib and cabozantinib. On 2L TKI therapy, one patient (1.5%) achieved a CR, 27 patients (39.7%) a PR and 36 patients (52.9%) SD. Median PFS was 13.2 months (95% CI: 10.1, NA). Forty-five percent of subjects required a dose reduction, and 27% of patients discontinued treatment because of toxicity ([@B157]). The efficacy and safety of VEGFR-TKIs after PD-1/PD-L1 inhibition were demonstrated by Nadal et al. in a retrospective study; as expected, the RR was lower and the mPFS was shorter in those patients who received prior anti PD-1/PD-L1 plus VEGF/VEGFRi vs. patients treated with prior IO alone ([@B158]). Prospective trial will be needed to re-assess the new sequence of anti PD-1/PD-L1 and VEGF/VEGFRi and their combination, particularly in the second-line setting, mostly after the impressive results of the combination trials of immune checkpoint inhibitors and immune checkpoint inhibitors with VEGF/VEGFRi in the first-line therapy.

###### 

Medical treatment of mRCC according to EAU guidelines.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  **IMDC risk group**     **First-line therapy**                 **Second-line therapy**                        **Third line therapy**
  ----------------------- -------------------------------------- ---------------------------------------------- -----------------------------------------
  Favorable               Sunitinib or pazopanib                 Cabozantinib or nivolumab                      Cabozantinib or nivolumab

  Intermediate and poor   Ipilimumab+nivolumab\                  Cabozantinib or other VEGF targeted therapy\   Cabozantinib or other targeted therapy\
                          Cabozantinib, sunitinib or pazopanib   VEGF targeted therapy or nivolumab             Other targeted therapy or nivolumab
  -------------------------------------------------------------------------------------------------------------------------------------------------------

*European Association of Urology guidelines accessed at <https://uroweb.org/guideline/renal-cell-carcinoma/#7> on 6th May 2019. VEGF, vascular endothelial growth factor; IMDC, International Metastatic RCC Database Consortium*.

Conclusions {#s5}
===========

As summarized in [Table 4](#T4){ref-type="table"}, we reviewed the most promising predictive and prognostic available biomarkers in RCC patients treated with antiangiogenic agents. With the advent of novel immunotherapy agents, the clinical need to personalize treatment has become more compelling. At the present time, there are no effective biomarkers that can be incorporated in the therapeutic algorithm, despite large research efforts. Most available data come from large retrospective analyses or even small samples and can only establish a trend, but require prospective validation in order to be considered practice-changing. Novel genomic and transcriptomic biomarkers, such as circulating tumor DNA and miRNA in serum or plasma, have great potential to become practice-changing in the future, as they can reflect deep aspects of tumor biology and can be assessed non-invasively and at decreasing costs.

###### 

Main prognostic and predictive statistically significant biomarkers reviewed.

  **References**                  **Patient population**   **Biomarker(s)**                                                                **Sample size**   **Main findings**
  ------------------------------- ------------------------ ------------------------------------------------------------------------------- ----------------- -------------------------------------------------------------------------------------------------
  D\' Alterio et al. ([@B41])     mRCC                     CXCR4 Negative/Low vs. Mod vs. High expression                                  62                HR for progression in patients treated with sunitinib = 2.04; *p* = 0.0271
                                                                                                                                                             HR for death in patients treated with sunitinib = 1.48 (95%CI = 0.93--2.38); *p* = 0.0974
  Motzer et al. ([@B43])          advanced RCC             HIF1a low vs. high expression                                                   292               HR for progression in patients treated with sunitinib = 1.55; *p* = 0.0341
                                                                                                                                                             HR for death in patients treated with sunitinib = 1.34; *p* = 0.2095
  Rini et al. ([@B51])            mRCC                     sVEGFR-3 less than median baseline value vs. greater than median serum levels   59                HR for progression in patients treated with sunitinib = 0.45; *p* = 0.006
                                                           VEGF-C less than median baseline value vs. greater than median serum levels     57                HR for progression in patients treated wit sunitinib = 0.37; *p* = 0.0006
  Tran et al. ([@B53])            mRCC                     Interleukin 6 low serum levels                                                  344               HR for progression in patients treated with pazopanib vs. interferon = 0.55; *p* = 0.009
                                                           Interleukin 6 high serum levels                                                                   HR for progression in patients treated with pazopanib vs. interferon = 0.31; *p* = 0.009
                                                           Interleukin 6 low serum levels                                                                    HR for death in patients treated with pazopanib vs. interferon = 1.41; *p* = 0.005
                                                           Interleukin 6 high serum levels                                                                   HR for death in patients treated with pazopanib vs. interferon = 0.42; *p* = 0.005
                                                           Interleukin 8 low serum levels                                                                    HR for death in patients treated with pazopanib vs. interferon = 1.49; *p* = 0.002
                                                           Interleukin 8 high serum levels                                                                   HR for death in patients treated with pazopanib vs. interferon = 0.42; *p* = 0.002
                                                           Osteopontin low serum levels                                                                      HR for death in patients treated with pazopanib vs. interferon = 0.96; *p* = 0.033
                                                           Osteopontin high serum levels                                                                     HR for death in patients treated with pazopanib vs. interferon = 0.41; *p* = 0.033
                                                           VEGF low serum levels                                                                             HR for death in patients treated with pazopanib vs. interferon = 1.2; *p* = 0.006
                                                           VEGF high serum levels                                                                            HR for death in patients treated with pazopanib vs. interferon = 0.41; *p* = 0.006
  Peña et al. ([@B62])            Advanced RCC             VEGF high vs. low expression                                                    348               HR for death in patients treated with sorafenib = 1.64; *p* = 0.0027
                                                           CAIX high vs. low expression                                                    66                HR for death in patients treated with sorafenib = 2.26; *p* = 0.034
                                                           TIMP-1 high vs. low expression                                                  63                HR for death in patients treated with sorafenib = 3.34; *p* = 0.001
                                                           Ras p21 high vs. low expression                                                 65                HR for death in patients treated with sorafenib = 2.49; *p* = 0.016
  Xu et al. ([@B72])              Advanced/mRCC            IL8 2767TT genotype vs. IL8 wild-type AA genotype                               397               HR for progression in patients treated with pazopanib = 1.8; *p* = 0.009
                                                           IL8 251AA genotype vs. IL8 wild-type TT genotype                                                  HR for progression in patients treated with pazopanib = 1.7; *p* = 0.01
                                                           HIF1a 1790AG genotype vs. HIF1a wild type GG genotype                                             HR for progression in patients treated with pazopanib = 1.8; *p* = 0.03
  Xu et al. ([@B74])              Advanced RCC             IL8 rs1126647 polymorphism, variant T allele vs. reference variant A            186               HR for death in patients treated with pazopanib = 1.45; *p* = 0.007
                                                                                                                                           337               HR for death in patients treated with sunitinib = 1.39; *p* = 0.008
                                                                                                                                           88                HR for death in patients treated with sunitinib = 1.62; *p* = 0.034
  Garcia-Donas et al. ([@B75])    Advanced RCC             VEGFR3 rs307826 AA variant vs. AG varian                                        95                HR for progression in patients treated with sunitinib = 3.57; *p* = 0.0079
                                                           VEGFR3 rs307821 GG variant vs. GT variant                                                         HR for progression in patients treated with sunitinib = 3.31 (95% CI = 1.64--6.68); *p* = 0.014
  van der Veldt et al. ([@B77])   mRCC                     ABCB1 other haplotypes vs. TCG haplotype                                        129               HR for progression in patients treated with sunitinib = 0.52; *p* = 0.033
                                                           CYP3A5 6986A/G GG haplotype vs. AG+AA haplotypes                                128               HR for progression in patients treated with sunitinib = 0.26; *p* = 0.032
  Escudier et al. ([@B78])        mRCC                     VEGFR2 rs2071559 AA variant vs. GG variant                                      141               HR for progression in patients treated with sorafenib = 2.22; *p* = 0.0053
                                                           VEGFR2 rs2071559 AA variant vs. GG variant                                                        HR for death in patients treated with sorafenib = 2.58; *p* = 0.0027
                                                           VEGFR2 rs1870377 TT variant vs. TA variant                                      47                HR for progression in patients treated with sorafenib = 0.62; *p* = 0.026
                                                           HIF-1α rs11549465 CC variant vs. CT variant                                     33                HR for progression in patients treated with axitinib = 1.93; *p* = 0.006
                                                                                                                                                             HR for death in patients treated with axitinib = 1.88; *p* = 0.007
                                                           VEGF-A rs699947 CC variant vs. AA variant                                       42                HR for death in patients treated with axitinib = 0.39; *p* = 0.001

*mRCC, metastatic renal cell carcinoma; VEGF, vascular endothelial growth factor; CXCR, chemokine receptor; HIF, hypoxia-inducible factors; VEGFR, vascular endothelial growth factor receptor; TIMP−1, metallopeptidase inhibitor 1; KDR, kinase insert domain receptor; CAIX, Carbonic Anhydrase IX; IL, interleukin; ABCB1, ATP binding cassette subfamily B member 1; CYP3A5, cytochrome P450 family 3 subfamily A member; ABCG2, ATP-binding cassette super-family G member*.
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